First Time Loading...

Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196

Watchlist Manager
Shanghai Fosun Pharmaceutical Group Co Ltd Logo
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Watchlist
Price: 24.12 CNY 1.9% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one Shanghai Fosun Pharmaceutical Group Co Ltd stock under the Base Case scenario is 53.72 CNY. Compared to the current market price of 24.12 CNY, Shanghai Fosun Pharmaceutical Group Co Ltd is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
53.72 CNY
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
93
vs Industry
62
Median 3Y
2.1
Median 5Y
2.5
Industry
2.5
Forward
1.4
More Details
27
P/E
P/E
Price to Earnings
27
vs History
38
vs Industry
19
Median 3Y
25.7
Median 5Y
25.7
Industry
23.4
Forward
20.7
More Details
18.9
P/OCF
P/OCF
Price to OCF
18.9
vs History
92
vs Industry
24
Median 3Y
22.4
Median 5Y
24.4
Industry
17.4
More Details
600.7
P/FCFE
P/FCFE
Price to FCFE
600.7
vs History
3
vs Industry
1
Median 3Y
44
Median 5Y
36.1
Industry
23.6
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
93
vs Industry
53
Median 3Y
2.1
Median 5Y
2.4
Industry
2.1
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
93
vs Industry
54
Median 3Y
2.4
Median 5Y
2.9
Industry
2.6
Forward
1.8
More Details
4.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.1
vs History
92
vs Industry
50
Median 3Y
5.1
Median 5Y
5.6
Industry
5.2
More Details
62.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
62.8
vs History
19
vs Industry
4
Median 3Y
51.9
Median 5Y
47.7
Industry
13.7
Forward
12.1
More Details
62.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
62.8
vs History
19
vs Industry
5
Median 3Y
51.9
Median 5Y
47.7
Industry
17.2
Forward
33.4
More Details
23.7
EV/OCF
EV/OCF
Enterprise Value to OCF
23.7
vs History
77
vs Industry
20
Median 3Y
25.6
Median 5Y
28.1
Industry
16.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-60.3
Median 5Y
-90
Industry
17.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
93
vs Industry
63
Median 3Y
1.2
Median 5Y
1.4
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Shanghai Fosun Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
64.4B CNY 1.6 27 62.8 62.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
716.9B USD 20 116.8 57.2 65.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.4 45.4 33.2 36.2
US
Johnson & Johnson
NYSE:JNJ
357.6B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
321.2B USD 5.2 139.3 33.2 52.6
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.8
CH
Novartis AG
SIX:NOVN
180B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
174.5B CHF 3 15.2 8.6 10.3
US
Pfizer Inc
NYSE:PFE
158.8B USD 2.9 -513.9 12.8 20.3
P/E Multiple
Earnings Growth
CN
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Average P/E: 50.7
27
62%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
116.8
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.4
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
139.3
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.4
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.2
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -513.9
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.